Your browser is no longer supported. Please, upgrade your browser.
CYCN Cyclerion Therapeutics, Inc. daily Stock Chart
Cyclerion Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.74 Insider Own0.80% Shs Outstand26.73M Perf Week-82.87%
Market Cap61.48M Forward P/E- EPS next Y-2.34 Insider Trans- Shs Float26.66M Perf Month-73.41%
Income-129.80M PEG- EPS next Q-1.30 Inst Own73.50% Short Float4.48% Perf Quarter-72.85%
Sales1.60M P/S38.42 EPS this Y-22.70% Inst Trans0.20% Short Ratio4.04 Perf Half Y-85.50%
Book/sh5.15 P/B0.45 EPS next Y60.50% ROA-200.20% Target Price5.00 Perf Year-
Cash/sh5.27 P/C0.44 EPS next 5Y- ROE-452.10% 52W Range2.27 - 22.85 Perf YTD-81.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-90.72% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low-6.61% ATR1.57
Employees140 Current Ratio6.60 Sales Q/Q- Oper. Margin- RSI (14)28.10 Volatility18.12% 14.25%
OptionableNo Debt/Eq0.00 EPS Q/Q41.40% Profit Margin- Rel Volume10.07 Prev Close2.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume295.37K Price2.12
Recom3.00 SMA20-74.38% SMA50-78.82% SMA200-82.31% Volume503,859 Change-7.83%
Jun-03-19Initiated Credit Suisse Neutral
Nov-01-19 10:52AM  Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks
Oct-31-19 08:08AM  The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut Benzinga -13.09%
Oct-30-19 09:24AM  Cyclerion's stock plummets to pace premarket losers after diabetes treatment study missed primary endpoint MarketWatch -79.52%
08:17AM  Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
07:31AM  Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy GlobeNewswire
07:30AM  Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF) GlobeNewswire
Oct-08-19 08:00AM  Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings GlobeNewswire
Sep-25-19 01:22PM  Read This Before Selling Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares Simply Wall St.
Sep-10-19 08:00AM  Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17 GlobeNewswire
Aug-12-19 08:00AM  Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months GlobeNewswire -5.45%
Jul-31-19 10:58AM  Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks
Jul-24-19 03:23PM  What Kind Of Shareholders Own Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)? Simply Wall St. -5.39%
Jun-11-19 08:30AM  Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP GlobeNewswire
Jun-05-19 09:50AM  Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 Zacks -6.64%
Jun-04-19 01:58PM  3 Spinoff Stocks Worth Your Attention
08:30AM  Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings GlobeNewswire
May-13-19 07:00AM  Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company GlobeNewswire -9.38%
Apr-25-19 08:00AM  Cyclerion to Host Corporate Overview Call on May 13, 2019 GlobeNewswire
Apr-09-19 05:37AM  Cyclerion taps ex-Shire exec as chief innovation officer American City Business Journals +8.16%
Apr-02-19 08:00AM  Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases GlobeNewswire -36.59%
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its lead product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of serious cardiometabolic diseases, such as diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for serious and orphan central nervous system diseases. The company's products that are in discovery stage include liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.